SCHEMBL16100129

SCHEMBL16100129

COc1cc(Cl)c(Cl)cc1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.61
GAA P10253 3/20 0.53
KDM4E B2RXH2 2/20 0.53
RECQL P46063 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
CASP3 P42574 1/20 0.49
HSD17B10 Q99714 2/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46
MAOB P27338 1/20 0.45
GRM5 P41594 2/20 0.45
RAB9A P51151 1/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2108026 0.85 RXFP1 (0.54) RXFP1GAAKDM4ERECQLMEN1
SCHEMBL22400685 0.82 RXFP1 (0.61) RXFP1GAAKDM4ERECQLMEN1
SCHEMBL18669183 0.80 GAA (0.78) RXFP1GAAKDM4ERECQLMEN1
SCHEMBL9387548 0.79 RAB9A (0.60) RXFP1GAAKDM4ERECQLMEN1
SCHEMBL18669194 0.78 GAA (0.59) RXFP1GAAKDM4ERECQLMEN1
SCHEMBL3024201 0.78 CASP3 (0.58) RXFP1KDM4EKMT2ACYP1A2CYP3A4
SCHEMBL6687632 0.78 RXFP1 (0.71) RXFP1GAAKDM4ERECQLMEN1
SCHEMBL6940053 0.78 CASP3 (0.58) RXFP1KDM4ECASP3LMNAALDH1A1
SCHEMBL6939477 0.78 CASP3 (0.58) RXFP1KDM4ECASP3LMNAALDH1A1
SCHEMBL2567485 0.77 RXFP1 (0.55) RXFP1GAAKDM4ERECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3401314-B1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-11-08 EP disclosed
CN-109890797-B Substituted carbon nucleoside derivatives useful as anticancer agents 辉瑞公司 2023-02-28 CN disclosed
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 EP disclosed
US-10919850-B2 Covalent inhibitors of KRas G12C ARAXES PHARMA LLC (US) 2021-02-16 US disclosed
EP-3193851-B1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2020-10-21 EP disclosed
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2020-07-14 US disclosed
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2019-08-29 US disclosed
US-10273207-B2 Covalent inhibitors of kras G12C ARAXES PHARMA LLC (US) 2019-04-30 US disclosed
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2019-04-18 US disclosed
EP-3464249-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Inc (US) 2019-04-10 EP disclosed
US-20160159738-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2016-06-09 US disclosed
US-20160159738-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2016-06-09 US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 WO disclosed
EP-2970121-A1 COVALENT INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2016-01-20 EP disclosed
US-9227978-B2 Covalent inhibitors of Kras G12C ARAXES PHARMA LLC (US) 2016-01-05 US disclosed
US-9227978-B2 Covalent inhibitors of Kras G12C ARAXES PHARMA LLC (US) 2016-01-05 US disclosed
WO-2014152588-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2014-09-25 WO disclosed
WO-2014152588-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2014-09-25 WO disclosed
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2014-09-25 US disclosed
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2014-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS RXFP1 4611/4885GAA 1747/4885KDM4E 1936/4885
US-20160159738-A1 COVALENT INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS RXFP1 4611/4885GAA 1747/4885KDM4E 1936/4885
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP RXFP1 4862/4885GAA 297/4885KDM4E 2891/4885
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP RXFP1 4862/4885GAA 297/4885KDM4E 2891/4885
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS RXFP1 4386/4885GAA 2526/4885KDM4E 4202/4885
US-10919850-B2 Covalent inhibitors of KRas G12C KRAS, NRAS, HRAS RXFP1 4611/4885GAA 1747/4885KDM4E 1936/4885
US-10273207-B2 Covalent inhibitors of kras G12C KRAS, NRAS, HRAS RXFP1 4611/4885GAA 1747/4885KDM4E 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.